Published online Feb 28, 2020. doi: 10.3748/wjg.v26.i8.789
Peer-review started: October 3, 2019
First decision: November 10, 2019
Revised: December 20, 2019
Accepted: February 12, 2020
Article in press: February 12, 2020
Published online: February 28, 2020
Processing time: 147 Days and 18.3 Hours
Tumor microenvironments (TMEs) play an important role in cancer development, including hepatocellular carcinoma (HCC), hence affecting clinical outcomes. Stromal and immune cells are two major components of nontumor cells in TMEs and are considered to be valuable for the prognostic evaluation of tumors. Nonetheless, the infiltration level of stromal/immune cells and specific roles of TME-related genes in HCC have not yet been clarified.
More biomarkers are required for the diagnosis and treatment of HCC.
The present study investigated potential key genes associated with tumor microenvironments and the prognosis of HCC.
The ESTIMATE method was used to predict the infiltration levels of stromal and immune cells in HCC. Differentially expressed genes (DEGs) between patients with high and low infiltration levels were screened using the TCGA database and linked to overall survival of HCC. DEGs were verified by four other independent HCC cohorts and further selected by LASSO Cox regression analysis.
HCC patients with high immune/stromal infiltration levels had better survival benefits than patients with low infiltration levels. A total of 147 DEGs were identified to be associated with overall survival. Moreover, 52 survival-related DEGs were validated, and ten key genes were selected by LASSO algorithm, which were further used to construct a prognostic classifier, showing a good performance in predicting overall survival.
Our study screened a series of TME-related genes and provided a novel insight into the potential association of TME with HCC prognosis and molecular targeted therapy of HCC in the future.
HCC and TMEs are an integral whole. More in-depth research should be conducted to reveal the important role of components of TMEs in HCC to develop novel anti-cancer treatments via targeting TME-related cells and the extracellular matrix.
